1. Klaus W. Pharmacology of molsidomine. In: Bing RJ Stauch M, eds. Ischemic Heart Disease and Heart Failure: Advances in Treatment with Molsidomine. Munich: Urban Schwarzenberg 1986:3?9.
2. Cano JP, Guillen JC, Jouve R, Langlet F, Puddu PE, Rolland PH, Serradimigni A. Molsidomine prevents post-ischaemic ventricular fibrillation in dogs. Br J Pharmacol 1986;88:779?789.
3. Chignard M, Delautier D, Poincelot B, Russo-Marie F, Gateau O, Benveniste J. Effect of SIN-1 on platelet activation. In: Bing RJ, Stauch M, eds. Ischemic Heart Disease and Heart Failure: Advances in Treatment with Molsidomine. Munich: Urban Schwartzenberg, 1986:39?42.
4. Martorana PA, Ritz RE. Treatment of thrombosis-induced acute myocardial infarction with molsidomine in an animal model. In: Bing RJ, Stauch M, eds. Ischemic Heart Disease and Heart Failure: Advances in Treatment with Molsidomine. Munich: Urban Schwartzenberg, 1986:10?14.
5. Meinertz T, Branstatter A, Trenk D, Jahnchen E, Ostrowski J, Gartner W. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolism in man. In: Bing RJ, Stauch M, eds. Ischemic Heart Disease and Heart Failure: Advances in Treatment with Molsidomine. Munich: Urban Schwartzenberg, 1986:43?50.